Skip to content

HIV Resistance Workshop 2003: resistance in non-B HIV subtypes

High-dose pulsed therapy - the future for structured treatment breaks?

Response to HAART in first 18 months determines five-year prognosis

African HIV epidemic in the UK examined in study

HAART patients have increased risk of heart disease say French

Asylum seekers should not be forced to take HIV test, say MPs

A blueprint for ARV care?

Long cycle treatment breaks unsafe and do not lessen side-effects or improve CD4 count or viral load

3TC resistant HBV common in HIV/HBV coinfected HAART treated patients

UK law which banned 'promotion of homosexuality' and obstructed HIV prevention passes into history

AZT resistance may be reversed by rheumatic drug

IAS conference opens in Paris with calls for global treatment access

Two years after switch to abacavir, only one third of limb fat returns

Low CD4 predicts earlier onset of creatinine elevation on HAART

d4T dose reduction improves lipoatrophy in Thai patients

HAART effective at preventing illness and death in babies

Over 50s have lower viral load, no link found to type of therapy, adherence or CD4 count

HAART not a risk factor for anaemia, but AZT, low CD4 counts are, and prognosis remains poor